Advertisement

EASL Recommendations on Treatment of Hepatitis C 2016

  • European Association for the Study of the Liver
Published:September 21, 2016DOI:https://doi.org/10.1016/j.jhep.2016.09.001
      Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide [
      • Lavanchy D.
      Evolving epidemiology of hepatitis C virus.
      ]. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 180 million [
      • Messina J.P.
      • Humphreys I.
      • Flaxman A.
      • Brown A.
      • Cooke G.S.
      • Pybus O.G.
      • et al.
      Global distribution and prevalence of hepatitis C virus genotypes.
      ], but most are unaware of their infection. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lavanchy D.
        Evolving epidemiology of hepatitis C virus.
        Clin Microbiol Infect. 2011; 17: 107-115
        • Messina J.P.
        • Humphreys I.
        • Flaxman A.
        • Brown A.
        • Cooke G.S.
        • Pybus O.G.
        • et al.
        Global distribution and prevalence of hepatitis C virus genotypes.
        Hepatology. 2015; 61: 77-87
        • Arase Y.
        • Kobayashi M.
        • Suzuki F.
        • Suzuki Y.
        • Kawamura Y.
        • Akuta N.
        • et al.
        Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
        Hepatology. 2013; 57: 964-973
        • van der Meer A.J.
        • Veldt B.J.
        • Feld J.J.
        • Wedemeyer H.
        • Dufour J.F.
        • Lammert F.
        • et al.
        Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
        JAMA. 2012; 308: 2584-2593
        • Bruno S.
        • Di Marco V.
        • Iavarone M.
        • Roffi L.
        • Crosignani A.
        • Calvaruso V.
        • et al.
        Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
        J Hepatol. 2016; 64: 1217-1223
        • Negro F.
        • Forton D.
        • Craxi A.
        • Sulkowski M.S.
        • Feld J.J.
        • Manns M.P.
        Extrahepatic morbidity and mortality of chronic hepatitis C.
        Gastroenterology. 2015; 149: 1345-1360
        • Andrews J.
        • Guyatt G.
        • Oxman A.D.
        • Alderson P.
        • Dahm P.
        • Falck-Ytter Y.
        • et al.
        GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.
        J Clin Epidemiol. 2013; 66: 719-725
        • Chevaliez S.
        • Pawlotsky J.M.
        Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.
        Best Pract Res Clin Gastroenterol. 2008; 22: 1031-1048
        • Kamili S.
        • Drobeniuc J.
        • Araujo A.C.
        • Hayden T.M.
        Laboratory diagnostics for hepatitis C virus infection.
        Clin Infect Dis. 2012; 55: S43-S48
        • Bulteel N.
        • Partha Sarathy P.
        • Forrest E.
        • Stanley A.J.
        • Innes H.
        • Mills P.R.
        • et al.
        Factors associated with spontaneous clearance of chronic hepatitis C virus infection.
        J Hepatol. 2016; 65: 266-272
        • Chevaliez S.
        • Feld J.
        • Cheng K.
        • Wedemeyer H.
        • Sarrazin C.
        • Maasoumy B.
        • et al.
        Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen.
        Antivir Ther. 2016; ([Epub ahead of print])
        • Chevaliez S.
        • Soulier A.
        • Poiteau L.
        • Bouvier-Alias M.
        • Pawlotsky J.M.
        Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C.
        J Clin Virol. 2014; 61: 145-148
        • Chhatwal J.
        • Wang X.
        • Ayer T.
        • Kabiri M.
        • Chung R.T.
        • Hur C.
        • et al.
        Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals.
        Hepatology. 2016; ([Epub ahead of print])
        • Pawlotsky J.M.
        The end of the hepatitis C burden: really?.
        Hepatology. 2016; ([Epub ahead of print])
        • Chevaliez S.
        • Poiteau L.
        • Rosa I.
        • Soulier A.
        • Roudot-Thoraval F.
        • Laperche S.
        • et al.
        Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.
        Clin Microbiol Infect. 2016; 22: 459e451–e456
        • Khuroo M.S.
        • Khuroo N.S.
        • Khuroo M.S.
        Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis.
        PLoS One. 2015; 10e0121450
        • Shivkumar S.
        • Peeling R.
        • Jafari Y.
        • Joseph L.
        • Pant Pai N.
        Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis.
        Ann Intern Med. 2012; 157: 558-566
        • Poiteau L.
        • Soulier A.
        • Rosa I.
        • Roudot-Thoraval F.
        • Hezode C.
        • Pawlotsky J.M.
        • et al.
        Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
        J Viral Hepat. 2016; 23: 399-401
        • Soulier A.
        • Poiteau L.
        • Rosa I.
        • Hezode C.
        • Roudot-Thoraval F.
        • Pawlotsky J.M.
        • et al.
        Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring.
        J Infect Dis. 2016; 213: 1087-1095
        • Tuaillon E.
        • Mondain A.M.
        • Meroueh F.
        • Ottomani L.
        • Picot M.C.
        • Nagot N.
        • et al.
        Dried blood spot for hepatitis C virus serology and molecular testing.
        Hepatology. 2010; 51: 752-758
        • Martinot-Peignoux M.
        • Stern C.
        • Maylin S.
        • Ripault M.P.
        • Boyer N.
        • Leclere L.
        • et al.
        Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
        Hepatology. 2010; 51: 1122-1126
        • Swain M.G.
        • Lai M.Y.
        • Shiffman M.L.
        • Cooksley W.G.
        • Zeuzem S.
        • Dieterich D.T.
        • et al.
        A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
        Gastroenterology. 2010; 139: 1593-1601
        • Freiman J.M.
        • Tran T.M.
        • Schumacher S.G.
        • White L.F.
        • Ongarello S.
        • Cohn J.
        • et al.
        Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis.
        Ann Intern Med. 2016; ([Epub ahead of print])
        • Aghemo A.
        • Degasperi E.
        • De Nicola S.
        • Bono P.
        • Orlandi A.
        • D’Ambrosio R.
        • et al.
        Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection.
        Clin Gastroenterol Hepatol. 2016; 14: 1331-1336
        • European Association for Study of the Liver
        • Asociacion Latinoamericana para el Estudio del Higado
        EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
        J Hepatol. 2015; 63: 237-264
        • Castera L.
        • Sebastiani G.
        • Le Bail B.
        • de Ledinghen V.
        • Couzigou P.
        • Alberti A.
        Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
        J Hepatol. 2010; 52: 191-198
        • Castera L.
        • Vergniol J.
        • Foucher J.
        • Le Bail B.
        • Chanteloup E.
        • Haaser M.
        • et al.
        Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
        Gastroenterology. 2005; 128: 343-350
        • Chevaliez S.
        • Bouvier-Alias M.
        • Brillet R.
        • Pawlotsky J.M.
        Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.
        PLoS One. 2009; 4e8209
        • Fourati S.
        • Pawlotsky J.M.
        Virologic tools for HCV drug resistance testing.
        Viruses. 2015; 7: 6346-6359
        • Pawlotsky J.M.
        Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens.
        Gastroenterology. 2016; 151: 70-86
        • Terrault N.A.
        • Zeuzem S.
        • Di Bisceglie A.M.
        • Lim J.K.
        • Pockros P.J.
        • Frazier L.M.
        • et al.
        Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response.
        Gastroenterology. 2016; ([Epub ahead of print])
        • Huisman M.T.
        • Snoeys J.
        • Monbaliu J.
        • Martens M.A.
        • Sekar V.J.
        • Raoof A.
        In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters.
        Hepatology. 2010; 52: 461A-462A
        • Mauss S.
        • Buggish P.
        • Boker K.H.W.
        • Schott E.
        • Klinker H.
        • Gunther R.
        • et al.
        Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals: data from the German Hepatitis C Registry.
        J Hepatol. 2016; 64: S820
        • Sulkowski M.S.
        • Vargas H.E.
        • Di Bisceglie A.M.
        • Kuo A.
        • Reddy K.R.
        • Lim J.K.
        • et al.
        Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection.
        Gastroenterology. 2016; 150: 419-429
        • Jensen D.M.
        • O’Leary J.G.
        • Pockros P.J.
        • Sherman K.E.
        • Kwo P.Y.
        • Mailliard M.E.
        • et al.
        Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort.
        Hepatology. 2014; 60: 219A
        • Dieterich D.
        • Bacon B.R.
        • Flamm S.L.
        • Kowdley K.V.
        • Milligan S.
        • Tsai N.
        • et al.
        Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population.
        Hepatology. 2014; 60: 220A
        • European Association for Study of the Liver
        EASL Recommendations on Treatment of Hepatitis C 2015.
        J Hepatol. 2015; 63: 199-236
      1. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection.
        J Hepatol. 2011; 55: 245-264
      2. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection.
        J Hepatol. 2014; 60: 392-420
        • Afdhal N.
        • Zeuzem S.
        • Kwo P.
        • Chojkier M.
        • Gitlin N.
        • Puoti M.
        • et al.
        Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1889-1898
        • Afdhal N.
        • Reddy K.R.
        • Nelson D.R.
        • Lawitz E.
        • Gordon S.C.
        • Schiff E.
        • et al.
        Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1483-1493
        • Kowdley K.V.
        • Gordon S.C.
        • Reddy K.R.
        • Rossaro L.
        • Bernstein D.E.
        • Lawitz E.
        • et al.
        Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
        N Engl J Med. 2014; 370: 1879-1888
        • Naggie S.
        • Cooper C.
        • Saag M.
        • Workowski K.
        • Ruane P.
        • Towner W.J.
        • et al.
        Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.
        N Engl J Med. 2015; 373: 705-713
        • Curry M.
        • Modi A.A.
        • Pungpapong S.
        • Leise M.
        • Aqel B.
        • LLewellyn J.
        • et al.
        Real-world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts.
        J Hepatol. 2016; 64: S797
        • Vermehren J.
        • Maasoumy B.
        • Maan R.
        • Cloherty G.
        • Berkowski C.
        • Feld J.J.
        • et al.
        Applicability of hepatitis C virus RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C virus genotype 1 infection.
        Clin Infect Dis. 2016; 62: 1228-1234
        • Townsend K.S.
        • Osinusi A.
        • Nelson A.K.
        • Kohli A.
        • Gross C.
        • Polis M.A.
        • et al.
        High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on and off antiretroviral therapy: results from the NIAID ERADICATE trial.
        Hepatology. 2014; 60: 240A-241A
        • Bourlière M.
        • Sulkowski M.S.
        • Omata M.
        • Zeuzem S.
        • Feld J.J.
        • Lawitz E.
        • et al.
        An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin.
        Hepatology. 2014; 60: 239A
        • Bourlière M.
        • Bronowicki J.P.
        • de Ledinghen V.
        • Hézode C.
        • Zoulim F.
        • Mathurin P.
        • et al.
        Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy.
        Hepatology. 2014; 60: 1271A
        • Zeuzem S.
        • Mizokami M.
        • Pianko S.
        • Mangia A.
        • Han K.H.
        • Martin R.
        • et al.
        Prevalence of pretreatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF.
        Hepatology. 2015; 62: 254A
        • Sarrazin C.
        The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
        J Hepatol. 2016; 64: 486-504
        • Feld J.J.
        • Jacobson I.M.
        • Hezode C.
        • Asselah T.
        • Ruane P.J.
        • Gruener N.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.
        N Engl J Med. 2015; 373: 2599-2607
        • Wyles D.
        • Brau N.
        • Kottilil S.
        • Daar E.
        • Workowski K.
        • Luetkemeyer A.
        • et al.
        Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients coinfected with HCV and HIV-1: the Phase 3 ASTRAL-5 study.
        J Hepatol. 2016; 64: S188-S189
        • Feld J.J.
        • Kowdley K.V.
        • Coakley E.
        • Sigal S.
        • Nelson D.R.
        • Crawford D.
        • et al.
        Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
        N Engl J Med. 2014; 370: 1594-1603
        • Ferenci P.
        • Bernstein D.
        • Lalezari J.
        • Cohen D.
        • Luo Y.
        • Cooper C.
        • et al.
        ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
        N Engl J Med. 2014; 370: 1983-1992
        • Dore G.J.
        • Conway B.
        • Luo Y.
        • Janczewska E.
        • Knysz B.
        • Liu Y.
        • et al.
        Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
        J Hepatol. 2016; 64: 19-28
        • Wyles D.L.
        • Sulkowski M.S.
        • Eron J.J.
        • Trinh R.
        • Lalezari J.
        • Slim J.
        • et al.
        TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin.
        Hepatology. 2014; 60: 1136A-1137A
        • Zeuzem S.
        • Jacobson I.M.
        • Baykal T.
        • Marinho R.T.
        • Poordad F.
        • Bourliere M.
        • et al.
        Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
        N Engl J Med. 2014; 370: 1604-1614
        • Andreone P.
        • Colombo M.G.
        • Enejosa J.V.
        • Koksal I.
        • Ferenci P.
        • Maieron A.
        • et al.
        ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
        Gastroenterology. 2014; 147: 359-365e351
        • Poordad F.
        • Hezode C.
        • Trinh R.
        • Kowdley K.V.
        • Zeuzem S.
        • Agarwal K.
        • et al.
        ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
        N Engl J Med. 2014; 370: 1973-1982
        • Feld J.J.
        • Moreno C.
        • Trinh R.
        • Tam E.
        • Bourgeois S.
        • Horsmans Y.
        • et al.
        Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
        J Hepatol. 2016; 64: 301-307
        • Rockstroh J.K.
        • Nelson M.
        • Katlama C.
        • Lalezari J.
        • Mallolas J.
        • Bloch M.
        • et al.
        Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
        Lancet HIV. 2015; 2: e319-e327
        • Zeuzem S.
        • Rockstroh J.
        • Kwo P.Y.
        • Roth D.
        • Lawitz E.
        • Sulkowski M.S.
        • et al.
        Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)-infected patients: integrated analysis of Phase 2–3 trials.
        Hepatology. 2015; 62: 554A-555A
        • Kwo P.
        • Gane E.
        • Peng C.Y.
        • Pearlman B.
        • Vierling J.M.
        • Serfaty L.
        • et al.
        Efficacy and safety of grazoprevir/elbasvir plus or minus RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE Treatment-Experienced trial.
        J Hepatol. 2015; 62: S674-S675
        • Sulkowski M.S.
        • Gardiner D.F.
        • Rodriguez-Torres M.
        • Reddy K.R.
        • Hassanein T.
        • Jacobson I.
        • et al.
        Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
        N Engl J Med. 2014; 370: 211-221
        • Luetkemeyer A.F.
        • McDonald C.
        • Ramgopal M.
        • Noviello S.
        • Bhore R.
        • Ackerman P.
        12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens.
        Clin Infect Dis. 2016; 62: 1489-1496
        • Poordad F.
        • Schiff E.R.
        • Vierling J.M.
        • Landis C.
        • Fontana R.J.
        • Yang R.
        • et al.
        Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
        Hepatology. 2016; 63: 1493-1505
        • Foster G.R.
        • Afdhal N.
        • Roberts S.K.
        • Brau N.
        • Gane E.J.
        • Pianko S.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
        N Engl J Med. 2015; 373: 2608-2617
        • Nelson D.R.
        • Cooper J.N.
        • Lalezari J.P.
        • Lawitz E.
        • Pockros P.J.
        • Gitlin N.
        • et al.
        All-Oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase 3 Study.
        Hepatology. 2015; 61: 1127-1135
        • Leroy V.
        • Angus P.
        • Bronowicki J.P.
        • Dore G.J.
        • Hezode C.
        • Pianko S.
        • et al.
        Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
        Hepatology. 2016; 63: 1430-1441
        • Kapoor R.
        • Kohli A.
        • Sidharthan S.
        • Sims Z.
        • Petersen T.L.
        • Osinusi A.
        • et al.
        All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial.
        Hepatology. 2014; 60: 321A
        • Abergel A.
        • Metivier S.
        • Samuel D.
        • Jiang D.
        • Kersey K.
        • Pang P.S.
        • et al.
        Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
        Hepatology. 2016; ([Epub ahead of print])
        • Pol S.
        • Reddy K.R.
        • Baykal T.
        • Hezode C.
        • Hassanein T.
        • Marcellin P.
        • et al.
        Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results.
        Hepatology. 2014; 60: 1129A
        • Asselah T.
        • Hezode C.
        • Qaqish R.B.
        • Elkhasbab M.
        • Hassanein T.
        • Papatheodoridis G.V.
        • et al.
        High SVR rates in patients with genotype 4 chronic hepatitis C infection and compensated cirrhosis with ombitasvir/paritaprevir/ritonavir co-administered with ribavirin (AGATE-I).
        J Hepatol. 2016; 64: S827
        • Zeuzem S.
        • Ghalib R.
        • Reddy K.R.
        • Pockros P.J.
        • Ben Ari Z.
        • Zhao Y.
        • et al.
        Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial.
        Ann Intern Med. 2015; 163: 1-13
        • Buti M.
        • Calleja J.L.
        • Forns X.
        • Diago M.
        • Ortega E.
        • Crespo J.
        • et al.
        Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: a Phase III open-label study.
        J Hepatol. 2016; 64: S220-S221
        • Abergel A.
        • Asselah T.
        • Metivier S.
        • Kersey K.
        • Jiang D.
        • Mo H.
        • et al.
        Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
        Lancet Infect Dis. 2016; 16: 459-464
        • Gane E.J.
        • Hyland R.H.
        • An D.
        • Svarovskaia E.S.
        • Pang P.S.
        • Symonds W.T.
        • et al.
        High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection.
        Hepatology. 2014; 60: 1274A
        • Garcia-Retortillo M.
        • Forns X.
        • Feliu A.
        • Moitinho E.
        • Costa J.
        • Navasa M.
        • et al.
        Hepatitis C virus kinetics during and immediately after liver transplantation.
        Hepatology. 2002; 35: 680-687
        • Gane E.
        • Pilmore H.
        Management of chronic viral hepatitis before and after renal transplantation.
        Transplantation. 2002; 74: 427-437
        • Flamm S.L.
        • Everson G.T.
        • Charlton M.
        • Denning J.M.
        • Arterburn S.
        • Brandt-Sarif T.
        • et al.
        Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study.
        Hepatology. 2014; 60: 320A
        • Curry M.P.
        • Forns X.
        • Chung R.T.
        • Terrault N.A.
        • Brown Jr., R.
        • Fenkel J.M.
        • et al.
        Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
        Gastroenterology. 2015; 148: 100-107e101
        • Zuckerman E.
        • Ashkenazi E.
        • Kovalev Y.
        • Weitsman E.
        • Kaspa R.T.
        • Brown M.
        • et al.
        The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: a large multi-center cohort.
        J Hepatol. 2016; 64: S137
        • Flisiak R.
        • Jaroszewicz J.
        • Janczewska E.
        • Wawrzynowicz-Syczewska M.
        • Grabinska A.
        • Bolewska B.
        • et al.
        Predictors of hepatic decompensation during ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin treatment of genotype 1 and 4 HCV infected patients (real-life AMBER study).
        J Hepatol. 2016; 64: S815
        • Charlton M.
        • Everson G.T.
        • Flamm S.L.
        • Kumar P.
        • Landis C.
        • Brown Jr, R.S.
        • et al.
        Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.
        Gastroenterology. 2015; 149: 649-659
        • Manns M.
        • Samuel D.
        • Gane E.J.
        • Mutimer D.
        • McCaughan G.
        • Buti M.
        • et al.
        Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
        Lancet Infect Dis. 2016; 16: 685-697
        • Curry M.P.
        • O’Leary J.G.
        • Bzowej N.
        • Muir A.J.
        • Korenblat K.M.
        • Fenkel J.M.
        • et al.
        Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.
        N Engl J Med. 2015; 373: 2618-2628
        • Foster G.R.
        • Irving W.L.
        • Cheung M.C.
        • Walker A.J.
        • Hudson B.E.
        • Verma S.
        • et al.
        Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
        J Hepatol. 2016; 64: 1224-1231
        • Cheung M.C.
        • Walker A.J.
        • Hudson B.E.
        • Verma S.
        • McLauchlan J.
        • Mutimer D.J.
        • et al.
        Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
        J Hepatol. 2016; 65: 741-747
        • Belli L.S.
        • Berenguer M.
        • Cortesi P.A.
        • Strazzabosco M.
        • Rockenschaub S.R.
        • Martini S.
        • et al.
        Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.
        J Hepatol. 2016; 65: 524-531
        • Forman L.M.
        • Lewis J.D.
        • Berlin J.A.
        • Feldman H.I.
        • Lucey M.R.
        The association between hepatitis C infection and survival after orthotopic liver transplantation.
        Gastroenterology. 2002; 122: 889-896
        • Prieto M.
        • Berenguer M.
        • Rayon J.M.
        • Cordoba J.
        • Arguello L.
        • Carrasco D.
        • et al.
        High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
        Hepatology. 1999; 29: 250-256
        • Blasco A.
        • Forns X.
        • Carrion J.A.
        • Garcia-Pagan J.C.
        • Gilabert R.
        • Rimola A.
        • et al.
        Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation.
        Hepatology. 2006; 43: 492-499
        • Neumann U.P.
        • Berg T.
        • Bahra M.
        • Seehofer D.
        • Langrehr J.M.
        • Neuhaus R.
        • et al.
        Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
        J Hepatol. 2004; 41: 830-836
        • Charlton M.
        • Gane E.
        • Manns M.P.
        • Brown Jr., R.S.
        • Curry M.P.
        • Kwo P.Y.
        • et al.
        Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
        Gastroenterology. 2015; 148: 108-117
        • Forns X.
        • Charlton M.
        • Denning J.
        • McHutchison J.G.
        • Symonds W.T.
        • Brainard D.
        • et al.
        Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation.
        Hepatology. 2015; 61: 1485-1494
        • Flamm S.
        • Bacon B.
        • Curry M.
        • Dieterich D.
        • Guest L.
        • Kowdley K.V.
        • et al.
        Ledipasvir/sofosbuvir ± ribavirin in HCV post-transplant patients: real-world heterogeneous population from the TRIO network.
        J Hepatol. 2016; 64: S822
        • Ciesek S.
        • Proske V.
        • Otto B.
        • Pischke S.
        • Costa R.
        • Luthgehetmann M.
        • et al.
        Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
        Transplant Infect Dis. 2016; 18: 326-332
        • Coilly A.
        • Fougerou-Leurent C.
        • de Ledinghen V.
        • Houssel-Debry P.
        • Duvoux C.
        • Di Martino V.
        • et al.
        Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study.
        J Hepatol. 2016; 65: 711-718
        • Mantry P.S.
        • Kwo P.Y.
        • Coakley E.
        • Te H.S.
        • Vargas H.E.
        • Brown R.S.
        • et al.
        High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/r/ombitasvir plus dasabuvir plus ribavirin.
        Hepatology. 2014; 60: 298A-299A
        • Coilly A.
        • Pageaux G.P.
        • Houssel-Debry P.
        • Duvoux C.
        • Radenne S.
        • De Ledinghen V.
        • et al.
        Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs?.
        Hepatology. 2015; 62: 257A
        • Fernandez-Carrillo C.
        • Lens S.
        • Llop E.
        • Pascasio J.M.
        • Fernandez I.
        • Baliellas C.
        • et al.
        Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the HEPA-C registry.
        J Hepatol. 2016; 64: S133
        • Moon C.
        • Jung K.S.
        • Kim D.Y.
        • Baatarkhuu O.
        • Park J.Y.
        • Kim B.K.
        • et al.
        Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
        Dig Dis Sci. 2015; 60: 573-581
        • Morgan R.L.
        • Baack B.
        • Smith B.D.
        • Yartel A.
        • Pitasi M.
        • Falck-Ytter Y.
        Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.
        Ann Intern Med. 2013; 158: 329-337
        • Conti F.
        • Buonfiglioli F.
        • Scuteri A.
        • Crespi C.
        • Bolondi L.
        • Caraceni P.
        • et al.
        Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals.
        J Hepatol. 2016; 65: 727-733
        • Reig M.
        • Marino Z.
        • Perello C.
        • Inarrairaegui M.
        • Ribeiro A.
        • Lens S.
        • et al.
        Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
        J Hepatol. 2016; 65: 719-726
        • Camma C.
        • Cabibbo G.
        • Craxi A.
        Direct antiviral agents and risk for HCC early recurrence: much ado about nothing.
        J Hepatol. 2016; 65: 861-862
        • ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts)
        Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma.
        J Hepatol. 2016; 65: 734-740
        • Nault J.C.
        • Colombo M.
        Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution.
        J Hepatol. 2016; 65: 663-665
        • Potthoff A.
        • Berg T.
        • Wedemeyer H.
        Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon alpha-2b and ribavirin.
        Scand J Gastroenterol. 2009; 44: 1487-1490
        • Saadoun D.
        • Thibault V.
        • Si Ahmed S.N.
        • Alric L.
        • Mallet M.
        • Guillaud C.
        • et al.
        Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
        Ann Rheum Dis. 2016; ([Epub ahead of print])
        • Sise M.E.
        • Bloom A.K.
        • Wisocky J.
        • Lin M.V.
        • Gustafson J.L.
        • Lundquist A.L.
        • et al.
        Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
        Hepatology. 2016; 63: 408-417
        • Lim L.Y.
        • La D.
        • Cserti-Gazdewich C.M.
        • Shah H.
        Lymphoma remission by interferon-free HCV eradication without chemotherapy.
        ACG Case Rep J. 2015; 3: 69-70
        • Sultanik P.
        • Klotz C.
        • Brault P.
        • Pol S.
        • Mallet V.
        Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
        Blood. 2015; 125: 2446-2447
        • Saxena V.
        • Koraishy F.M.
        • Sise M.E.
        • Lim J.K.
        • Schmidt M.
        • Chung R.T.
        • et al.
        Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
        Liver Int. 2016; 36: 807-816
      3. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf.

        • Desnoyer A.
        • Pospai D.
        • Le M.P.
        • Gervais A.
        • Heurgue-Berlot A.
        • Laradi A.
        • et al.
        Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
        J Hepatol. 2016; 65: 40-47
        • Bhamidimarri K.R.
        • Czul F.
        • Peyton A.
        • Levy C.
        • Hernandez M.
        • Jeffers L.
        • et al.
        Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease.
        J Hepatol. 2015; 63: 763-765
        • Bhamidimarri K.R.
        • Martin P.
        Finally, safe and effective treatment options for hepatitis C in hemodialysis patients.
        J Hepatol. 2016; 65: 7-10
        • Hundemer G.L.
        • Sise M.E.
        • Wisocky J.
        • Ufere N.
        • Friedman L.S.
        • Corey K.E.
        • et al.
        Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
        Infect Dis (Lond). 2015; 47: 924-929
        • Perumpail R.B.
        • Wong R.J.
        • Ha L.D.
        • Pham E.A.
        • Wang U.
        • Luong H.
        • et al.
        Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
        Transplant Infect Dis. 2015; 17: 275-278
        • Wanchoo R.
        • Thakkar J.
        • Schwartz D.
        • Jhaveri K.D.
        Harvoni (ledipasvir with sofosbuvir)-induced renal injury.
        Am J Gastroenterol. 2016; 111: 148-149
        • Pockros P.J.
        • Reddy K.R.
        • Mantry P.S.
        • Cohen E.
        • Bennett M.
        • Sulkowski M.S.
        • et al.
        Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease.
        Gastroenterology. 2016; 150: 1590-1598
        • Roth D.
        • Nelson D.R.
        • Bruchfeld A.
        • Liapakis A.
        • Silva M.
        • Monsour Jr, H.
        • et al.
        Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
        Lancet. 2015; 386: 1537-1545
        • Beinhardt S.
        • Al Zoairy R.
        • Ferenci P.
        • Kozbial K.
        • Freissmuth C.
        • Stern R.
        • et al.
        DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post-kidney transplantation setting.
        Transplant Int. 2016; ([Epub ahead of print])
        • Kamar N.
        • Marion O.
        • Rostaing L.
        • Cointault O.
        • Ribes D.
        • Lavayssiere L.
        • et al.
        Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
        Am J Transplant. 2016; 16: 1474-1479
        • Lin M.V.
        • Sise M.E.
        • Pavlakis M.
        • Amundsen B.M.
        • Chute D.
        • Rutherford A.E.
        • et al.
        Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection.
        PLoS One. 2016; 11e0158431
        • Colombo M.
        • Aghemo A.
        • Liu L.
        • Zhang J.
        • Dvory-Sobol H.
        • Hyland R.H.
        • et al.
        Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic genotype 1 or 4 HCV infection: a randomized trial.
        J Ann Intern Med. 2016; ([In revision])
        • Scott D.R.
        • Wong J.K.
        • Spicer T.S.
        • Dent H.
        • Mensah F.K.
        • McDonald S.
        • et al.
        Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand.
        Transplantation. 2010; 90: 1165-1171
        • Van Wagner L.B.
        • Baker T.
        • Ahya S.N.
        • Norvell J.P.
        • Wang E.
        • Levitsky J.
        Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
        J Hepatol. 2009; 51: 874-880
        • D’Ambrosio R.
        • Aghemo A.
        • Rossetti V.
        • Carrinola R.
        • Colombo M.
        Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
        Liver Int. 2016; ([Epub ahead of print])
        • Darke S.
        • Kaye S.
        • Duflou J.
        Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes.
        Addiction. 2006; 101: 1771-1777
        • Grebely J.
        • Raffa J.D.
        • Lai C.
        • Kerr T.
        • Fischer B.
        • Krajden M.
        • et al.
        Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.
        J Viral Hepat. 2011; 18: 32-41
        • Hagan H.
        • Pouget E.R.
        • Des Jarlais D.C.
        • Lelutiu-Weinberger C.
        Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.
        Am J Epidemiol. 2008; 168: 1099-1109
        • Nelson P.K.
        • Mathers B.M.
        • Cowie B.
        • Hagan H.
        • Des Jarlais D.
        • Horyniak D.
        • et al.
        Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
        Lancet. 2011; 378: 571-583
        • Shepard C.W.
        • Finelli L.
        • Alter M.J.
        Global epidemiology of hepatitis C virus infection.
        Lancet Infect Dis. 2005; 5: 558-567
        • Grebely J.
        • Robaeys G.
        • Bruggmann P.
        • Aghemo A.
        • Backmund M.
        • Bruneau J.
        • et al.
        Recommendations for the management of hepatitis C virus infection among people who inject drugs.
        Int J Drug Policy. 2015; 26: 1028-1038
        • Martin N.K.
        • Vickerman P.
        • Foster G.R.
        • Hutchinson S.J.
        • Goldberg D.J.
        • Hickman M.
        Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility.
        J Hepatol. 2011; 54: 1137-1144
        • Martin N.K.
        • Vickerman P.
        • Miners A.
        • Foster G.R.
        • Hutchinson S.J.
        • Goldberg D.J.
        • et al.
        Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.
        Hepatology. 2012; 55: 49-57
        • Harris R.J.
        • Martin N.K.
        • Rand E.
        • Mandal S.
        • Mutimer D.
        • Vickerman P.
        • et al.
        New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.
        J Viral Hepat. 2016; 23: 631-643
        • Lalezari J.
        • Sullivan J.G.
        • Varunok P.
        • Galen E.
        • Kowdley K.V.
        • Rustgi V.
        • et al.
        Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
        J Hepatol. 2015; 63: 364-369
        • Dore G.
        • Altice F.
        • Litwin A.H.
        • Dalgard O.
        • Gane E.J.
        • Shibolet O.
        • et al.
        C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy.
        Hepatology. 2015; 62: 227A-228A
        • Smolders E.J.
        • de Kanter C.T.
        • de Knegt R.J.
        • van der Valk M.
        • Drenth J.P.
        • Burger D.M.
        Drug-drug interactions between direct-acting antivirals and psychoactive medications.
        Clin Pharmacokinet. 2016; ([Epub ahead of print])
        • Lai M.E.
        • Origa R.
        • Danjou F.
        • Leoni G.B.
        • Vacquer S.
        • Anni F.
        • et al.
        Natural history of hepatitis C in thalassemia major: a long-term prospective study.
        Eur J Haematol. 2013; 90: 501-507
        • Hezode C.
        • Colombo M.
        • Spengler U.
        • Ben-Ari Z.
        • Strasser S.
        • Lee W.M.
        • et al.
        C-EDGE IBLD: efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in subjects with chronic hepatitis C virus infection and inherited blood disorders.
        J Hepatol. 2016; 64: S753
        • Chevaliez S.
        • Bouvier-Alias M.
        • Brillet R.
        • Pawlotsky J.M.
        Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.
        Hepatology. 2007; 46: 22-31
        • Sarrazin C.
        • Shiffman M.L.
        • Hadziyannis S.J.
        • Lin A.
        • Colucci G.
        • Ishida H.
        • et al.
        Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
        J Hepatol. 2010; 52: 832-838
        • Vermehren J.
        • Kau A.
        • Gartner B.C.
        • Gobel R.
        • Zeuzem S.
        • Sarrazin C.
        Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.
        J Clin Microbiol. 2008; 46: 3880-3891
        • Renard S.
        • Borentain P.
        • Salaun E.
        • Benhaourech S.
        • Maille B.
        • Darque A.
        • et al.
        Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir.
        Chest. 2016; 149: e69-e73
        • Fried M.W.
        • Shiffman M.L.
        • Reddy K.R.
        • Smith C.
        • Marinos G.
        • Goncales Jr, F.L.
        • et al.
        Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
        N Engl J Med. 2002; 347: 975-982
        • Hadziyannis S.J.
        • Sette Jr., H.
        • Morgan T.R.
        • Balan V.
        • Diago M.
        • Marcellin P.
        • et al.
        Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
        Ann Intern Med. 2004; 140: 346-355
        • Manns M.P.
        • McHutchison J.G.
        • Gordon S.C.
        • Rustgi V.K.
        • Shiffman M.
        • Reindollar R.
        • et al.
        Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
        Lancet. 2001; 358: 958-965
        • Fried M.W.
        Side effects of therapy of hepatitis C and their management.
        Hepatology. 2002; 36: S237-S244
        • Shiffman M.L.
        • Salvatore J.
        • Hubbard S.
        • Price A.
        • Sterling R.K.
        • Stravitz R.T.
        • et al.
        Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
        Hepatology. 2007; 46: 371-379
        • Soza A.
        • Everhart J.E.
        • Ghany M.G.
        • Doo E.
        • Heller T.
        • Promrat K.
        • et al.
        Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
        Hepatology. 2002; 36: 1273-1279
        • Afdhal N.H.
        • Dieterich D.T.
        • Pockros P.J.
        • Schiff E.R.
        • Shiffman M.L.
        • Sulkowski M.S.
        • et al.
        Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
        Gastroenterology. 2004; 126: 1302-1311
        • Pockros P.J.
        • Shiffman M.L.
        • Schiff E.R.
        • Sulkowski M.S.
        • Younossi Z.
        • Dieterich D.T.
        • et al.
        Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
        Hepatology. 2004; 40: 1450-1458
        • Sulkowski M.S.
        • Poordad F.
        • Manns M.P.
        • Bronowicki J.P.
        • Rajender Reddy K.
        • Harrison S.A.
        • et al.
        Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
        Hepatology. 2013; 57: 974-984
        • Alavian S.M.
        • Aalaei-Andabili S.H.
        Education by a nurse increases the adherence to therapy in chronic hepatitis C patients.
        Clin Gastroenterol Hepatol. 2012; 10: 203
        • Rodis J.L.
        • Kibbe P.
        Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy.
        Gastroenterol Nurs. 2010; 33: 368-373
        • Alexander J.A.
        • Hearld L.R.
        • Mittler J.N.
        • Harvey J.
        Patient-physician role relationships and patient activation among individuals with chronic illness.
        Health Serv Res. 2012; 47: 1201-1223
        • Anand B.S.
        • Currie S.
        • Dieperink E.
        • Bini E.J.
        • Shen H.
        • Ho S.B.
        • et al.
        Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.
        Gastroenterology. 2006; 130: 1607-1616
        • Bruggmann P.
        • Dampz M.
        • Gerlach T.
        • Kravecz L.
        • Falcato L.
        Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.
        Drug Alcohol Depend. 2010; 110: 167-171
        • Le Lan C.
        • Guillygomarc’h A.
        • Danielou H.
        • Le Dreau G.
        • Laine F.
        • Vedeilhie C.
        • et al.
        A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse.
        J Hepatol. 2012; 56: 334-340
        • Siu L.
        • Foont J.
        • Wands J.R.
        Hepatitis C virus and alcohol.
        Semin Liv Dis. 2009; 29: 188-199
        • Backmund M.
        • Meyer K.
        • Edlin B.R.
        Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.
        Clin Infect Dis. 2004; 39: 1540-1543
        • Currie S.L.
        • Ryan J.C.
        • Tracy D.
        • Wright T.L.
        • George S.
        • McQuaid R.
        • et al.
        A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus.
        Drug Alcohol Depend. 2008; 93: 148-154
        • Dalgard O.
        Follow-up studies of treatment for hepatitis C virus infection among injection drug users.
        Clin Infect Dis. 2005; 40: S336-S338
        • Grebely J.
        • Knight E.
        • Ngai T.
        • Genoway K.A.
        • Raffa J.D.
        • Storms M.
        • et al.
        Reinfection with hepatitis C virus following sustained virological response in injection drug users.
        J Gastroenterol Hepatol. 2010; 25: 1281-1284
        • Grebely J.
        • Pham S.T.
        • Matthews G.V.
        • Petoumenos K.
        • Bull R.A.
        • Yeung B.
        • et al.
        Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
        Hepatology. 2012; 55: 1058-1069
        • Martin T.C.
        • Ingiliz P.
        • Rodger A.
        • Stellbrink H.J.
        • Mauss S.
        • Boesecke C.
        • et al.
        HCV reinfection incidence and outcomes among HIV infected MSM in Western Europe.
        J Hepatol. 2016; 64: S138
        • Wyles D.L.
        • Pockros P.J.
        • Yang J.C.
        • Zhu Y.
        • Pang P.S.
        • McHutchison J.G.
        • et al.
        Retreatment of patients who failed prior sofosbuvir-based regimens with all-oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks.
        Hepatology. 2014; 60: 317A
        • Hezode C.
        • Chevaliez S.
        • Scoazec G.
        • Soulier A.
        • Varaut A.
        • Bouvier-Alias M.
        • et al.
        Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
        Hepatology. 2016; 63: 1809-1816
        • Hezode C.
        • Fourati S.
        • Scoazec G.
        • Soulier A.
        • Varaut A.
        • Francois M.
        • et al.
        Retreatment of HCV DAA failures: HCV infection may be incurable.
        J Hepatol. 2016; 64: S400
        • Gane E.J.
        • Shiffman M.
        • Etzkorn K.
        • Morelli G.
        • Stedman C.
        • Davis M.N.
        • et al.
        Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A-containing DAA regimens: results of the retreatment study.
        J Hepatol. 2016; 64: S147
        • Poordad F.
        • Bennett M.
        • Sepe T.E.
        • Cohen E.
        • Reindollar R.W.
        • Everson G.
        • et al.
        Ombitasvir/paritaprevir/r, dasabuvir and sofosbuvir treatment of patients with genotype 1 infection who failed a prior course of DAA therapy: the QUARTZ-I study.
        J Hepatol. 2016; 64: S767-S768
        • Vermehren J.
        • Susser S.
        • Dietz J.
        • von Hahn T.
        • Petersen J.
        • Hinrichsen H.
        • et al.
        Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database.
        J Hepatol. 2016; 64: S188
        • Camma C.
        • Almasio P.
        • Craxi A.
        Interferon as treatment for acute hepatitis C. A meta-analysis.
        Dig Dis Sci. 1996; 41: 1248-1255
        • Gerlach J.T.
        • Diepolder H.M.
        • Zachoval R.
        • Gruener N.H.
        • Jung M.C.
        • Ulsenheimer A.
        • et al.
        Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.
        Gastroenterology. 2003; 125: 80-88
        • Micallef J.M.
        • Kaldor J.M.
        • Dore G.J.
        Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.
        J Viral Hepat. 2006; 13: 34-41
        • Poynard T.
        • Regimbeau C.
        • Myers R.P.
        • Thevenot T.
        • Leroy V.
        • Mathurin P.
        • et al.
        Interferon for acute hepatitis C.
        Cochrane Database Syst Rev. 2002; 1CD000369
        • Basu P.P.
        • Shah N.J.
        • Aloysius M.M.
        • Brown Jr, R.
        Sofosbuvir and ledipasvir vs. sofosbuvir and simeprevir for acute hepatitis C: a RCT (SLAM C study).
        Hepatol Int. 2016; 10: S14-S15
        • Rockstroh J.K.
        • Bhagani S.
        • Hyland R.H.
        • Yun C.
        • Zheng W.
        • Brainard D.
        • et al.
        Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection.
        in: Conference on Retroviruses and Opportunistic Infections (CROI), February 22–25, Boston, Massachusetts. 2016
        • Deterding K.
        • Spinner C.
        • Schott E.
        • Welzel T.
        • Gerken G.
        • Klinker H.
        • et al.
        Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study.
        J Hepatol. 2016; 64: S211

      Linked Article